Improving Staging in Bladder Cancer: The Increasing Role of Multiparametric Magnetic Resonance Imaging

European Urology Focus

Volumn 2, Issue 2, 2016, Pages 113-121

  Panebianco, Valeria ^a   Barchetti, Flavio ^a   de Haas, Robbert J ^b   Pearson, Rachel A ^c   Kennish, Steven J ^d   Giannarini, Gianluca ^e   Catto, James W F ^f  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c FREEMAN HOSPITAL   (United Kingdom)

^d SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bladder neoplasm; Diffusion magnetic resonance imaging; Lymph nodes; Multiparametric magnetic resonance imaging; Staging

Indexed keywords

ANTINEOPLASTIC AGENT; FERUMOXYTOL; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTIFACT REDUCTION; BLADDER CANCER; BLEEDING; CANCER CLASSIFICATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYSTECTOMY; CYSTOSCOPY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED IMAGING; FALSE POSITIVE RESULT; HUMAN; IMAGE PROCESSING; INFLAMMATION; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; PELVIS LYMPH NODE; PREDICTION; RADIATION RESPONSE; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; TUMOR DIFFERENTIATION;

EID: 84969792464     PISSN: None     EISSN: 24054569     Source Type: Journal    
DOI: 10.1016/j.euf.2016.04.010     Document Type: Review

References (53)

1. Chavan S., Bray F., Lortet-Tieulent J., Goodman M., Jemal A. International variations in bladder cancer incidence and mortality. Eur Urol 2014, 66:59-73.
2. Svatek R.S., Hollenbeck B.K., Holmäng S., et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur Urol 2014, 66:253-262.
3. Noon A., Albertsen P.C., Thomas F., et al. Competing mortality in patients diagnosed with bladder cancer: evidence of under-treatment in the elderly and females. Br J Cancer 2013, 108:1534-1540.
4. Ficarra V., Dalpiaz O., Alrabi N., et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 2005, 95:786-790.
5. Thomas F., Noon A., Rubin N., et al. Comparative outcomes of primary, recurrent and progressive high-risk non-muscle invasive bladder cancer. Eur Urol 2013, 63:145-154.
6. Goodfellow H., Viney Z., Hughes P., et al. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer. BJU Int 2014, 114:389-395.
7. de Haas R.J., Steyvers M.J., Fütterer J.J., Multiparametric M.R.I. of the bladder: ready for clinical routine?. AJR Am J Roentgenol 2014, 202:1187-1195.
8. Verma S., Rajesh A., Prasad S.R., et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012, 32:371-387.
9. Takeuchi M., Sasaki S., Ito M., et al. Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009, 251:112-121.
10. Watanabe H., Kanematsu M., Kondo H., Preoperative T., et al. staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value?. AJR Am J Roentgenol 2009, 192:1361-1366.
11. El-Assmy A., Abou-El-Ghar M.E., Mosbah A., et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009, 19:1575-1581.
12. Takeuchi M., Sasaki S., Naiki T., et al. MR imaging of urinary bladder cancer for T-staging: a review and a pictorial essay of diffusion-weighted imaging. J Magn Reson Imaging 2013, 38:1299-1309.
13. Lin W.C., Chen J.H. Pitfalls and limitations of diffusion-weighted magnetic resonance imaging in the diagnosis of urinary bladder cancer. Transl Oncol 2015, 8:217-230.
14. Kobayashi S., Koga F., Yoshida S., et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011, 21:2178-2186.
15. Wu L.M., Chen X.X., Xu J.R., et al. Clinical value of T2-weighted imaging combined with diffusion-weighted imaging in preoperative T staging of urinary bladder cancer: a large-scale, multiobserver prospective study on 3.0-T MRI. Acad Radiol 2013, 20:939-946.
16. Yamada Y., Kobayashi S., Isoshima S., et al. The usefulness of diffusion-weighted magnetic resonance imaging in bladder cancer staging and functional analysis. J Cancer Res Ther 2014, 10:878-882.
17. Ohgiya Y., Suyama J., Sai S., et al. Preoperative T. staging of urinary bladder cancer: efficacy of stalk detection and diagnostic performance of diffusion-weighted imaging at 3T. Magn Reson Med Sci 2014, 13:175-181.
18. Wang H.J., Pui M.H., Guo Y., et al. Diffusion-weighted MRI in bladder carcinoma: the differentiation between tumor recurrence and benign changes after resection. Abdom Imaging 2014, 39:135-141.
19. Avcu S., Koseoglu M.N., Ceylan K., et al. The value of diffusion-weighted MRI in the diagnosis of malignant and benign urinary bladder lesions. Br J Radiol 2011, 84:875-882.
20. Daggulli M., Onur M.R., Firdolas F., et al. Role of diffusion MRI and apparent diffusion coefficient measurement in the diagnosis, staging and pathological classification of bladder tumors. Urol Int 2011, 87:346-352.
21. Halefoglu A.M., Sen E.Y., Tanriverdi O., et al. Utility of diffusion-weighted MRI in the diagnosis of bladder carcinoma. Clin Imaging 2013, 37:1077-1083.
22. Matsuki M., Inada Y., Tatsugami F., et al. Diffusion-weighted MR imaging for urinary bladder carcinoma: initial results. Eur Radiol 2007, 17:201-204.
23. Kilickesmez O., Cimilli T., Inci E., et al. Diffusion-weighted MRI of urinary bladder and prostate cancers. Diagn Interv Radiol 2009, 15:104-110.
24. El-Assmy A., Abou-El-Ghar M.E., Refaie H.F., et al. Diffusion-weighted MR imaging in diagnosis of superficial and invasive urinary bladder carcinoma: a preliminary prospective study. Sci World J 2008, 8:364-370.
25. Abou-El-Ghar M.E., El-Assmy A., Refaie H.F., et al. Bladder cancer: diagnosis with diffusion-weighted MR imaging in patients with gross hematuria. Radiology 2009, 251:415-421.
26. Ceylan K., Taken K., Gecit I., et al. Comparison of cystoscopy with diffusion-weighted magnetic resonance images used in the diagnosis and follow-up of patients with bladder tumors. Asian Pac J Cancer Prev 2010, 11:1001-1004.
27. Zhou G., Chen X., Zhang J., et al. Contrast-enhanced dynamic and diffusion-weighted MR imaging at 3.0T to assess aggressiveness of bladder cancer. Eur J Radiol 2014, 83:2013-2018.
28. Sevcenco S., Ponhold L., Heinz-Peer G., et al. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urol Oncol 2014, 32:1166-1171.
29. Wang H.J., Pui M.H., Guo Y., et al. Multiparametric 3-T MRI for differentiating low-versus high-grade and category T1 versus T2 bladder urothelial carcinoma. AJR Am J Roentgenol 2015, 204:330-334.
30. Funatsu H., Imamura A., Takano H., et al. Can pretreatment ADC values predict recurrence of bladder cancer after transurethral resection?. Eur J Radiol 2012, 81:3115-3119.
31. Rosenkrantz A.B., Obele C., Rusinek H., et al. Whole-lesion diffusion metrics for assessment of bladder cancer aggressiveness. Abdom Imaging 2015, 40:327-332.
32. Rosenkrantz A.B., Mussi T.C., Spieler B., et al. High-grade bladder cancer: association of the apparent diffusion coefficient with metastatic disease: preliminary results. J Magn Reson Imaging 2012, 35:1478-1483.
33. El-Assmy A., Abou-El-Ghar M.E., Refaie H.F., et al. Diffusion-weighted magnetic resonance imaging in follow-up of superficial urinary bladder carcinoma after transurethral resection: initial experience. BJU Int 2012, 110:E622-E627.
34. Yoshida S., Koga F., Kobayashi S., et al. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2012, 83:e21-e27.
35. Giannarini G., Petralia G., Thoeny H.C. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012, 61:326-340.
36. Birkhäuser F.D., Studer U.E., Froehlich J.M., et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer. Eur Urol 2013, 64:953-960.
37. Yoshida S., Koga F., Kawakami S., et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010, 75:387-391.
38. Kim B., Semelka R.C., Ascher S.M., et al. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994, 193:239-245.
39. Narumi Y., Kadota T., Inoue E., et al. Bladder tumors: staging with gadolinium-enhanced oblique MR imaging. Radiology 1993, 187:145-150.
40. Scattoni V., Da Pozzo L.F., Colombo R., et al. Dynamic gadolinium-enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol 1996, 155:1594-1599.
41. Barentsz J.O., Jager G., Mugler J.P., et al. Staging urinary bladder cancer: value of T1-weighted three-dimensional magnetization prepared-rapid gradient-echo and two-dimensional spin-echo sequences. AJR Am J Roentgenol 1995, 164:109-115.
42. Daneshmand S., Ahmadi H., Huynh L.N., Dobos N. Preoperative staging of invasive bladder cancer with dynamic gadolinium-enhanced magnetic resonance imaging: results from a prospective study. Urology 2012, 80:1313-1318.
43. Gupta N., Sureka B., Kumar M.M., et al. Comparison of dynamic contrast-enhanced and diffusion weighted magnetic resonance image in staging and grading of carcinoma bladder with histopathological correlation. Urol Ann 2015, 7:199-204.
44. Rajesh A., Sokhi H.K., Fung R., Mulcahy K.A., Bankart M.J. Bladder cancer: evaluation of staging accuracy using dynamic MRI. Clin Radiol 2011, 66:1140-1145.
45. Tuncbilek N., Kaplan M., Altaner S., et al. Value of dynamic contrast-enhanced MRI and correlation with tumor angiogenesis in bladder cancer. AJR Am J Roentgenol 2009, 192:949-955.
46. Schrier B.P., Peters M., Barentsz J.O., Witjes J.A. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006, 49:698-703.
47. Chakiba C., Cornelis F., Descat E., et al. Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma. Eur J Radiol 2015, 84:1023-1028.
48. Barentsz J.O., Berger-Hartog O., Witjes J.A., et al. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging. Radiology 1998, 207:791-797.
49. Donaldson S.B., Bonington S.C., Kershaw L.E., et al. Dynamic contrast-enhanced MRI in patients with muscle-invasive transitional cell carcinoma of the bladder can distinguish between residual tumour and post-chemotherapy effect. Eur J Radiol 2013, 82:2161-2168.
50. Nguyen H.T., Jia G., Shah Z.K., et al. Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters. J Magn Reson Imaging 2015, 41:1374-1382.
51. Rais-Bahrami S., Pietryga J.A., Nix J.W. Contemporary role of advanced imaging for bladder cancer staging. Urol Oncol 2016, 34:124-133.
52. Triantafyllou M., Studer U.E., Birkhäuser F.D., et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer. Eur J Cancer 2013, 49:616-624.
53. Deserno W.M., Harisinghani M.G., Taupitz M., et al. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004, 233:449-456.